Meeting
2017 ASCO Annual Meeting
Selective benefit of adjuvant chemoradiation in resectable pancreatic cancer.
Authors
Jesse P Wright
Division of Surgical Oncology, Department of Surgery, Vanderbilt University Medical Center, Nasvhille, TN
Jesse P Wright , Cameron Schlegel , Rebecca A Snyder , Liping Du , Yu Shyr , Dana Backlund Cardin , Nipun B. Merchant , Alexander A. Parikh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Citation
J Clin Oncol 35, 2017 (suppl; abstr 4122)
DOI
10.1200/JCO.2017.35.15_suppl.4122
Abstract #
4122
Poster Bd #
114
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Chemotherapy dose density and effect on prognosis for patients with resectable pancreas cancer: A secondary analysis of SWOG S1505.
First Author: Sameer H. Patel
Poster
2013 Gastrointestinal Cancers Symposium
Phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy for resectable pancreatic cancer.
First Author: Katherine Fan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Adjuvant gemcitabine+S1 as adjuvant therapy for resectable pancreatic cancer: A real-world experience in a single-center retrospective study.
First Author: Hsin-Chen Lin
Poster
2021 ASCO Annual Meeting
Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.
First Author: Quisette Janssen